Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiologyheart failure, electrophysiologyhypertension, structural heart disease, use of pharmaceuticals, and COVID-19.   

FDA designates recall of Hamilton breathing circuits a Class I

Two lots of breathing circuits manufactured by Hamilton Medical have a defect that could cause the tubing to splinter. The affected devices must be quarantined, as they cannot be safely used on patients.

DOJ accuses nonprofit nursing homes of providing ‘grossly substandard’ care

Four nursing homes operated by ProMedica Health System are alleged to have failed to adequately feed patients, treat wounds and keep patients clean. The DOJ said the facilities falsified records to cover their tracks.

Nine former CDC leaders warn of ‘raging fire’ ignited by RFK

In an open letter published in the New York Times, former CDC directors call on Congress to mitigate threats to public health caused by mass layoffs and cuts to critical programs. 

Medtronic Symplicity Spyral renal denervation

Medtronic’s RDN system approved in Japan

Hypertension is a significant issue in Japan, impacting an estimated 43 million adults. Medtronic's Symplicity Spyral RDN system is now approved for the treatment of those patients. 

leg veins chronic venous disease PAD peripheral artery disease

Drug-coated balloons make little impact on PAD outcomes

Researchers tracked data from more than 3,000 patients, calling for more clinical trials of antiproliferative agents other than paclitaxel.

Biosense Webster, part of Johnson & Johnson MedTech, shared updated data on its Varipulse pulsed field ablation (PFA) system at AF Symposium 2024 in Boston,

Johnson & Johnson’s PFA platform is both safe and effective, real-world data confirm

The Varipulse PFA platform, which has already received FDA and CE mark approval, was linked to an adverse event rate of just 0.6%. 

Real-world data link semaglutide, tirzepatide to improved heart failure outcomes

GLP-1 drugs have been taking the United States by storm in recent years. According to a new study of more than 90,000 patients, some of these medications can also make a big impact on reducing adverse heart failure outcomes.

Beta blockers ‘have no effect’ on heart attack patients

One researcher described the study's findings as "one of the most significant advances in heart attack treatment in decades.”